1. Schneider D.T., Schuster A.E., Fritsch M.K. et al. Multipoint imprinting analysis indicates a common precursor cell for gonadal and nongonadal pediatric germ cell tumors//Cancer Res. - 2001. - Vol. 61, N 19. - P. 7268 - 7276.
2. McLaren A. Germ and somatic cell lineages in the developing gonad. Mol Cell Endocrinol. 2000; 163:3-9.
3. Saitou M, Barton SC, Surani MA. A molecular programme for the specification of germ cell fate in mice. Nature. 2002; 418:293-300.
4. Scholer HR, Dressier GR, Balling R, et al. Oct-4: a germline-specific transcription factor mapping to the mouse t-complex. EMBOJ. 1990; 9:2185-2195.
5. Hansis C, Grifo JA, Krey LC. Oct-4 expression in inner cell mass and trophectoderm of human blastocysts. Mol Hum Reprod. 2000; 6:999-1004.
6. Pesce M, Scholer HR. Oct-4: control of totipotency and germline determination. Mol Reprod Dev. 2000; 55:452-457.
7. Pesce M, Scholer HR. Oct-4: gatekeeper in the beginnings of mammalian development. Stem Cells. 2001; 19:271-278.
8. Rajpert-De Meyts E, Hanstein R, Jorgensen N, et al. Developmental expression of POU5F1 (OCT-3/4) in normal and dysge-netic human gonads. Hum Reprod. 2004; 19:1338-1344.
9. Hatano SY, Tada M, Kimura H, et al. Pluripotential competence of cells associated with Nanog activity. Mech Dev. 2005; 122: 67 - 79.
10. Yamaguchi S, Kimura H, Tada M, et al. Nanog expression in mouse germ cell development. Gene Expr Patterns. 2005; 5: 639 - 646.
11. Payer B, Chuva de Sousa Lopes SM, Barton SC, et al. Generation of stella-GFP transgenic mice: a novel tool to study germ cell development. Genesis. 2006; 44:75-83.
12. Buitrago W, DR. Oct-4: the almighty POUripotent regulator?) Invest Dermatol. 2007; 127:260-262.
13. Looijenga LH, Stoop H, de Leeuw HP, et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ eel tumors. Cancer Res. 2003; 63:2244-2250.
14. de Jong J, Stoop H, Dohle GR, et al. Diagnostic value of OCT3/4 for pre-invasive and invasive testicular germ cell tumours. ] Pathol. 2005; 206:242-249.
15. Hart AH, Hartley L, Parker K, et al. The pluripotency homeobox gene NANOG is expressed in human germ cell tumors. Cancer. 2005; 104:2092-2098.
16. Kersemaekers AM, Honecker F, Stoop H, et al. Identification of germ cells at risk for neoplastic transformation in gonadoblastoma: an immunohistochemical study for OCT3/4 and TSPY Hum Pathol. 2005; 36:512-521.
17. Cheng L, Sung MT, Cossu-Rocca P, et al. OCT4: biological functions and clinical applications as a marker of germ cell neoplasia. J Pathol. 2007; 211:1-9.
18. Rogers P.S., Olson T.A., Cullen J.W. et al. Treatment of children and adolescents with stage II testicular and stages II ovarian malignant germ cell tumors and I: A Pediatric Intergroup Study - Pediatric Oncology Group 9048 and Children's Cancer Group 8891//J Clin Oncol. - 2004. - Vol. 22, N 17. - P. 3663 - 3569.
19. Malogolowkin M.H., Monforte H.L., Kovanlikava A. et al. Pediatric germ cell tumors/Raghavan D. (eds). Germ cell tumors. - London: BC Decker Inc Hamilton, 2003. - P. 265 - 286.
20. Moller H., Evans H. Epidemiology of gonadal germ cell cancer in males and females//APMIS. - 2003. - Vol. 111, N 1. - P. 43 - 46.
21. Canto P., Kofman-Alfaro S., Jiminez A.L. et al. Gonadoblastoma in Turner syndrome patients with nonmosaic 45,X karyotype and Y chromosome sequences//Cancer Genet Cytogenet. - 2004. - Vol. 150, N 1. - P. - 70 - 72.
22. Carli M., Colombatti R., Oberlin O. et al. European intergroup studies (MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors//J Clin Oncol. - 2004. - Vol. 22, N 23. - P. 4787 - 4794.
23. Fizazi K., Prow D.M., Do K.A. et al. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumors//Br J Cancer. - 2002. - Vol. 86, N 10. - P. 1555 - 1560.
24. Guven S., Basaran M., Usubutum A. et al. Management of ovarian dysgerminoma during a pregnancy complicated by preeclampsia; a case report//Eur J Gynaecol Oncol. - 2004. - Vol. 25, N 6. - P. 759 - 760.
25. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancer. International Germ Cell Cancer Collaborative Group//J Clin Oncol. - 1997. - Vol. 15, N 2. - P. 594 - 603.
26. Dumesnil C., Gatbois E., Leverger G. Infantile choriocarcinoma: an uncommon and curable tumor//Arch Pediatr. - 2005. - Vol. 12, N 12. - P. 1721 - 1725.
27. Amato R.J., Ro J.Y., Ayala A.G. et al. Risk-adapted treatment for patient with clinical stage I nonseminomatous germ cell tumor of testis//Urology. - 2004. - Vol. 63, N 1. - P. 144 - 148.
28. Best D.H., Butz G.M., Moller K. et al. Molecular analysis of an immature ovarian teratoma with gliomatosis peritonei and recurrence suggests genetic independence of multiple tumors//Int J Oncol. - 2004. - Vol. 25, N 1. - P. 17 - 25.
29. Bhala N., Coleman J.M., Radstone C.R. et al. The manangement and survival of patients with advanced germ-cell tumors: improving outcome in intermediate and poor prognosis patients//Clin Oncol (R Coll Radiol). - 2004. - Vol. 16, N 1. - P. 40 - 47.
30. Chen Z., Robison L., Giller R. et al. Risk of childhood germ cell tumors in association with parental smoking and drinking//Cancer. - 2005. - Vol. 103, N 5. - P. 1064 - 1071.
31. Billmire D., Vinocur C., Rescoria F. et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study//J Pediatr Surg. - 2004. - Vol. 30, N 3. - P. 424 - 429.
32. Cushing B., Giller R., Cullen J.W., et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescent with high-risk malignant germ cell tumors: a pediatric intergroup study-Pediatric Oncology Group 9049 and Children's Cancer Group 8882//J Clin Oncol. - 2004. - Vol. 22, N 13. - P. 2691 - 700.
33. O'Connor D.M., Norris H.J. The influence of grade on the outcome of stage I ovarian immature (malignant) teratomas and the reproducibility of grading//Int J Gynecol Pathol. - 1994. - Vol. 13, N 4. - P. 283 - 289.